Literature DB >> 30303578

Epithelial-mesenchymal Transition and Cancer Stem Cells: At the Crossroads of Differentiation and Dedifferentiation.

Hanmin Wang1, Juli J Unternaehrer1.   

Abstract

In this review, we explore the connections between epithelial-mesenchymal transition (EMT) and differentiation status. EMTs in development have been described as differentiation events, while in most cases EMTs in cancer have been depicted as dedifferentiation events. We will briefly summarize both embryo development and cancer progression with regard to the involvement of EMT and cell differentiation status. We further present the studies that provide evidence that EMT results in both differentiation and dedifferentiation. Finally, we present our resolution to this dilemma by suggesting that EMT brings about dedifferentiation that enables subsequent differentiation. In normal development, EMT events may cause a partial reversal of differentiation to overcome differentiation barriers. When EMT is aberrantly activated in cancer, cells gain attributes of stem cells that contribute to self-renewal capabilities and are able to differentiate to all cell types represented in the tumor. The resulting cancer stem cells attain hallmarks of cancer, including replicative immortality, resistance to cell death, and invasiveness. Developmental Dynamics 248:10-20, 2019.
© 2018 Wiley Periodicals, Inc. © 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  development; differentiation; epithelial-mesenchymal transition; miRNA regulation; reprogramming

Mesh:

Year:  2018        PMID: 30303578     DOI: 10.1002/dvdy.24678

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  28 in total

Review 1.  Off to a Bad Start: Cancer Initiation by Pluripotency Regulator PRDM14.

Authors:  Lauren J Tracey; Monica J Justice
Journal:  Trends Genet       Date:  2019-05-23       Impact factor: 11.639

Review 2.  Bivalent Regulation and Related Mechanisms of H3K4/27/9me3 in Stem Cells.

Authors:  Han Sun; Yin Wang; Ying Wang; Feng Ji; An Wang; Ming Yang; Xu He; Lisha Li
Journal:  Stem Cell Rev Rep       Date:  2021-08-21       Impact factor: 5.739

Review 3.  The Role and Interactions of Programmed Cell Death 4 and its Regulation by microRNA in Transformed Cells of the Gastrointestinal Tract.

Authors:  William Frank Ferris
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

4.  Gene expression profile of epithelial-mesenchymal transition mediators in papillary thyroid cancer.

Authors:  Ana Lopez-Campistrous; Esther Ekpe Adewuyi; David C Williams; Todd P W McMullen
Journal:  Endocrine       Date:  2020-09-10       Impact factor: 3.633

5.  Asiaticoside inhibits epithelial-mesenchymal transition and stem cell-like properties of pancreatic cancer PANC-1 cells by blocking the activation of p65 and p38MAPK.

Authors:  Yonggang He; Xuehui Peng; Lu Zheng; Yichen Tang; Jing Li; Xiaobing Huang
Journal:  J Gastrointest Oncol       Date:  2021-02

6.  The Impact of Spaceflight and Microgravity on the Human Islet-1+ Cardiovascular Progenitor Cell Transcriptome.

Authors:  Victor Camberos; Jonathan Baio; Ana Mandujano; Aida F Martinez; Leonard Bailey; Nahidh Hasaniya; Mary Kearns-Jonker
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

7.  HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial-mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K/AKT and WNT/β-catenin signaling activation.

Authors:  Wei Tian; Jiatong Li; Zhuo Wang; Tong Zhang; Ying Han; Yanyan Liu; Wenfeng Chu; Yu Liu; Baofeng Yang
Journal:  Acta Pharm Sin B       Date:  2021-04-02       Impact factor: 11.413

Review 8.  Crosstalk between the oral microbiota, mucosal immunity, and the epithelial barrier regulates oral mucosal disease pathogenesis.

Authors:  Dongjia Lin; Lisa Yang; Liling Wen; Huanzi Lu; Qianming Chen; Zhi Wang
Journal:  Mucosal Immunol       Date:  2021-05-26       Impact factor: 7.313

9.  FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program.

Authors:  Ming Zhang; Rosalie G Hoyle; Zhikun Ma; Bo Sun; Weixin Cai; Hongshi Cai; Nan Xie; Yadong Zhang; Jinsong Hou; Xiqiang Liu; Demeng Chen; Glen E Kellogg; Hisashi Harada; Yue Sun; Cheng Wang; Jiong Li
Journal:  Mol Ther       Date:  2021-03-29       Impact factor: 12.910

10.  SMARCC1 Suppresses Tumor Progression by Inhibiting the PI3K/AKT Signaling Pathway in Prostate Cancer.

Authors:  Zhao-Ming Xiao; Dao-Jun Lv; Yu-Zhong Yu; Chong Wang; Tao Xie; Tao Wang; Xian-Lu Song; Shan-Chao Zhao
Journal:  Front Cell Dev Biol       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.